Aromatase Inhibitors Cost-Effective Compared To Tamoxifen, NICE Finds
This article was originally published in The Pink Sheet Daily
Although an overall survival advantage has not been shown, the U.K. agency recommends coverage of Arimidex, Aromasin and Femara.
You may also be interested in...
The U.K's National Institute for Health & Clinical Excellence released a final appraisal determination Aug. 11 supporting the clinical benefit of aromatase inhibitors over tamoxifen in primary adjuvant and unplanned switch treatment of early-stage breast cancer
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.